JP2022509258A5 - - Google Patents

Info

Publication number
JP2022509258A5
JP2022509258A5 JP2021530885A JP2021530885A JP2022509258A5 JP 2022509258 A5 JP2022509258 A5 JP 2022509258A5 JP 2021530885 A JP2021530885 A JP 2021530885A JP 2021530885 A JP2021530885 A JP 2021530885A JP 2022509258 A5 JP2022509258 A5 JP 2022509258A5
Authority
JP
Japan
Prior art keywords
isolated
dpep
seq
group
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021530885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509258A (ja
JP7535514B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/001289 external-priority patent/WO2020109864A1/en
Publication of JP2022509258A publication Critical patent/JP2022509258A/ja
Publication of JP2022509258A5 publication Critical patent/JP2022509258A5/ja
Priority to JP2024007364A priority Critical patent/JP2024028553A/ja
Application granted granted Critical
Publication of JP7535514B2 publication Critical patent/JP7535514B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021530885A 2018-11-30 2019-12-02 Ｄｐｅｐ－１結合剤および使用の方法 Active JP7535514B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024007364A JP2024028553A (ja) 2018-11-30 2024-01-22 Ｄｐｅｐ－１結合剤および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773733P 2018-11-30 2018-11-30
US62/773,733 2018-11-30
PCT/IB2019/001289 WO2020109864A1 (en) 2018-11-30 2019-12-02 Dpep-1 binding agents and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024007364A Division JP2024028553A (ja) 2018-11-30 2024-01-22 Ｄｐｅｐ－１結合剤および使用の方法

Publications (3)

Publication Number Publication Date
JP2022509258A JP2022509258A (ja) 2022-01-20
JP2022509258A5 true JP2022509258A5 (https=) 2022-10-05
JP7535514B2 JP7535514B2 (ja) 2024-08-16

Family

ID=70853301

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530885A Active JP7535514B2 (ja) 2018-11-30 2019-12-02 Ｄｐｅｐ－１結合剤および使用の方法
JP2024007364A Pending JP2024028553A (ja) 2018-11-30 2024-01-22 Ｄｐｅｐ－１結合剤および使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024007364A Pending JP2024028553A (ja) 2018-11-30 2024-01-22 Ｄｐｅｐ－１結合剤および使用の方法

Country Status (7)

Country Link
US (3) US11286278B2 (https=)
EP (1) EP3887390A4 (https=)
JP (2) JP7535514B2 (https=)
AU (1) AU2019386379B2 (https=)
CA (1) CA3121300A1 (https=)
IL (1) IL283231B1 (https=)
WO (1) WO2020109864A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7535514B2 (ja) * 2018-11-30 2024-08-16 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ－１結合剤および使用の方法
US20240254259A1 (en) * 2021-04-08 2024-08-01 National Research Council Canada Dpep-1 binding agents and methods of use
EP4574146A1 (en) 2023-12-18 2025-06-25 Telara Pharma S.L. Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223558B2 (en) * 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
WO2007081751A2 (en) * 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
WO2011131747A1 (en) * 2010-04-20 2011-10-27 Addex Pharma Sa Chimeric polypeptides useful in proximal and dynamic high-throughput screening methods
WO2012112420A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Treatments using psma ligand endopeptidases
EP3105245B1 (en) * 2014-02-13 2021-08-18 Arch Cancer Therapeutics, Inc. Peptides that block leukocyte recruitment and their therapeutic use
IL305285A (en) * 2015-08-11 2023-10-01 Arch Biopartners Inc DPEP-1 binding compositions and methods of use
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
JP7535514B2 (ja) * 2018-11-30 2024-08-16 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ－１結合剤および使用の方法

Similar Documents

Publication Publication Date Title
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
JP2025090743A5 (https=)
JP2006149365A5 (https=)
TWI653980B (zh) 治療及預防缺血性傷害之組成物與方法
JP2018171063A5 (https=)
JP2022509258A5 (https=)
JP2018509935A5 (https=)
EP2594581A3 (en) Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens
JP2011529084A5 (https=)
Ryge et al. New indolicidin analogues with potent antibacterial activity
NZ591130A (en) Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
Bhattacharjya NMR structures and interactions of antimicrobial peptides with lipopolysaccharide: Connecting structures to functions
JP2023528207A5 (https=)
JP2019525753A5 (https=)
ATE278708T1 (de) Conotoxin peptid pviia
JP2020526497A5 (https=)
FI4034555T3 (fi) Dap10/dap12-fuusiopolypeptidit
Ryge et al. Novel lysine‐peptoid hybrids with antibacterial properties
JP2019038772A5 (https=)
US20180201653A1 (en) Polypeptide compound and preparation method and use thereof
Bionda et al. Solid‐phase synthesis of fusaricidin/li‐f class of cyclic lipopeptides: Guanidinylation of resin‐bound peptidyl amines
RU2017104284A (ru) Выделенные полипептиды cd44 и их применение
KR20180086277A (ko) 폴리펩티드 화합물, 그리고 이의 제조 방법 및 적용
WO2020093055A3 (en) Peptide libraries with non-canonical amino acids
RU2011130796A (ru) Пептиды c1orf59 и содержащие их вакцины